INBRX 109
Alternative Names: INBRX-109; JCT-205Latest Information Update: 06 Nov 2023
At a glance
- Originator Inhibrx
- Developer Inhibrx; Transcenta Holding
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant proteins; Single-domain antibodies
- Mechanism of Action TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chondrosarcoma
- Phase I Solid tumours